287 related articles for article (PubMed ID: 30596395)
21. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
[TBL] [Abstract][Full Text] [Related]
22. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
[TBL] [Abstract][Full Text] [Related]
23. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
24. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
[TBL] [Abstract][Full Text] [Related]
26. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
27. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
[TBL] [Abstract][Full Text] [Related]
28. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
29. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
30. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.
Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
32. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
33. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody.
Taheri D; Zahavi DJ; Del Carmen Rodriguez M; Meliti A; Rezaee N; Yonescu R; Ricardo BF; Dolatkhah S; Ning Y; Bishop JA; Netto GJ; Sharma R
Virchows Arch; 2016 Sep; 469(3):345-50. PubMed ID: 27271275
[TBL] [Abstract][Full Text] [Related]
34. Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect.
Paolini D; Tiseo M; Demma F; Furneri G; Dionisi M; Akkermans M; Marchetti A
Clin Lung Cancer; 2018 Sep; 19(5):e735-e743. PubMed ID: 29937385
[TBL] [Abstract][Full Text] [Related]
35. Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
El Yacoubi H; Sow ML; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
BMC Cancer; 2020 May; 20(1):479. PubMed ID: 32460789
[TBL] [Abstract][Full Text] [Related]
36. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods.
Zwaenepoel K; Van Dongen A; Lambin S; Weyn C; Pauwels P
Histopathology; 2014 Oct; 65(4):539-48. PubMed ID: 24621075
[TBL] [Abstract][Full Text] [Related]
37. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
38. Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer.
Guo HQ; Jia J; Zhao LL; Zhao H; Wang C; Sun Y; Ying JM; Guo L; Cao J; Zhang ZH
BMC Cancer; 2018 Dec; 18(1):1277. PubMed ID: 30572846
[TBL] [Abstract][Full Text] [Related]
39. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
Singh A; Kumar R; Shetty O; Desai S; Rane S
Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
[TBL] [Abstract][Full Text] [Related]
40. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
